CRISPR screen reveals modifiers of rAAV production including known rAAV infection genes playing an unexpected role in vector production
Recombinant adeno-associated virus (rAAV) vectors are an effective and well-established tool in the growing gene therapy field, with five U.S. Food and Drug Administration-approved AAV-mediated gene therapies already on the market and numerous more in clinical trials. However, manufacturing rAAV vec...
Saved in:
Main Authors: | Emily E. O’Driscoll, Sakshi Arora, Jonathan F. Lang, Beverly L. Davidson, Ophir Shalem |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050125000038 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Secreted PD-L1 alleviates inflammatory arthritis in mice through local and systemic AAV gene therapy
by: Wenjun Li, et al.
Published: (2025-02-01) -
Systemic delivery of AAV5, AAV8, and AAV9 packaging a C5-12-microdystrophin-FLAG expression cassette in non-human primates
by: Mengping Liu, et al.
Published: (2025-03-01) -
A novel platform for engineered AAV-based vaccines
by: Sabrina Babutzka, et al.
Published: (2025-03-01) -
A versatile cell line for establishing potency of cell type-specific AAV transgenes
by: Refugio A. Martinez, et al.
Published: (2025-03-01) -
Recombinant AAV batch profiling by nanopore sequencing elucidates product-related DNA impurities and vector genome length distribution
by: Florian Dunker-Seidler, et al.
Published: (2025-03-01)